/
•
•
Detailed stories on technology startups, business and economic current affairs.
While earlier attempts were unsuccessful, with Glenmark running into huge losses, there seems to be growing consensus that the drugmaker’s R&D strategy makes it a different company. Perhaps even a valuable one.

On 10 December 2024, Glenmark Pharmaceuticals made a surprise announcement on the stock exchange. The Mumbai-based drugmaker shared clinical trial results from Ichnos Glenmark Innovation, its New York-based biotech arm. The company had achieved a significant breakthrough.
At the 66th annual meeting of the American Society of Hematology in San Diego, Ichnos had presented phase I data for its multispecific antibody targeting relapsed or refractory multiple myeloma (a type of incurable blood cancer). The results? An overall response rate of 75% in 20 patients, with 20% achieving complete remission.
This could make it a vital new drug in a high-growth …